sorafenib has been researched along with l-779,450 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (l-779,450) | Trials (l-779,450) | Recent Studies (post-2010) (l-779,450) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 15 | 0 | 11 |
| Protein | Taxonomy | sorafenib (IC50) | l-779,450 (IC50) |
|---|---|---|---|
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.0014 | |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | 0.01 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandhuber, BJ; Buckmelter, AJ; Callejo, M; Grina, J; Laird, ER; Lyssikatos, J; Martinson, M; Miknis, G; Morales, T; Randolph, N; Rast, B; Ren, L; Schlachter, S; Tarlton, E; Vigers, G; Welch, M; Wenglowsky, S | 1 |
1 other study(ies) available for sorafenib and l-779,450
| Article | Year |
|---|---|
The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
Topics: Animals; Binding Sites; Cell Line, Tumor; Computer Simulation; Drug Evaluation, Preclinical; Humans; Indans; Microsomes, Liver; Models, Chemical; Models, Molecular; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Rats; Structure-Activity Relationship | 2011 |